Immunoprecise Antibodies Stock Earnings Per Share

IPA Stock  USD 0.41  0.03  7.89%   
Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Immunoprecise Antibodies Company Earnings Per Share Analysis

Immunoprecise Antibodies' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Earnings per Share

 = 

Earnings

Average Shares

More About Earnings Per Share | All Equity Analysis

Current Immunoprecise Antibodies Earnings Per Share

    
  (0.77) X  
Most of Immunoprecise Antibodies' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunoprecise Earnings Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Immunoprecise Antibodies is extremely important. It helps to project a fair market value of Immunoprecise Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Immunoprecise Antibodies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunoprecise Antibodies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunoprecise Antibodies' interrelated accounts and indicators.
0.98-0.41-0.730.860.88-0.260.860.780.570.810.90.950.650.980.640.73-0.70.87-0.030.610.92-0.92
0.98-0.57-0.620.750.79-0.230.740.870.530.730.860.890.731.00.760.6-0.630.870.130.540.88-0.88
-0.41-0.57-0.190.0-0.130.070.06-0.87-0.18-0.14-0.16-0.18-0.83-0.57-0.930.220.15-0.31-0.61-0.08-0.230.27
-0.73-0.62-0.19-0.84-0.780.26-0.89-0.27-0.33-0.69-0.75-0.89-0.28-0.62-0.15-0.970.55-0.590.6-0.49-0.870.88
0.860.750.0-0.840.9-0.310.970.440.590.830.840.920.340.760.250.82-0.680.69-0.40.620.83-0.82
0.880.79-0.13-0.780.9-0.330.950.580.660.970.770.910.470.80.380.83-0.810.65-0.270.740.79-0.82
-0.26-0.230.070.26-0.31-0.33-0.3-0.18-0.29-0.36-0.26-0.28-0.14-0.26-0.13-0.220.29-0.210.03-0.27-0.220.22
0.860.740.06-0.890.970.95-0.30.420.580.880.820.940.330.750.220.91-0.730.68-0.440.680.84-0.84
0.780.87-0.87-0.270.440.58-0.180.420.430.560.530.610.920.860.960.26-0.50.570.330.410.62-0.66
0.570.53-0.18-0.330.590.66-0.290.580.430.770.570.520.130.530.210.32-0.920.530.110.920.38-0.34
0.810.73-0.14-0.690.830.97-0.360.880.560.770.710.840.420.730.360.75-0.870.6-0.230.820.7-0.73
0.90.86-0.16-0.750.840.77-0.260.820.530.570.710.890.330.850.360.72-0.610.92-0.040.530.91-0.83
0.950.89-0.18-0.890.920.91-0.280.940.610.520.840.890.540.890.470.89-0.690.8-0.30.610.96-0.97
0.650.73-0.83-0.280.340.47-0.140.330.920.130.420.330.540.740.960.27-0.280.380.120.190.56-0.66
0.981.0-0.57-0.620.760.8-0.260.750.860.530.730.850.890.740.760.6-0.640.870.130.540.87-0.88
0.640.76-0.93-0.150.250.38-0.130.220.960.210.360.360.470.960.760.12-0.290.460.370.20.51-0.57
0.730.60.22-0.970.820.83-0.220.910.260.320.750.720.890.270.60.12-0.570.57-0.610.510.84-0.86
-0.7-0.630.150.55-0.68-0.810.29-0.73-0.5-0.92-0.87-0.61-0.69-0.28-0.64-0.29-0.57-0.570.1-0.99-0.530.55
0.870.87-0.31-0.590.690.65-0.210.680.570.530.60.920.80.380.870.460.57-0.570.210.490.8-0.75
-0.030.13-0.610.6-0.4-0.270.03-0.440.330.11-0.23-0.04-0.30.120.130.37-0.610.10.21-0.12-0.230.3
0.610.54-0.08-0.490.620.74-0.270.680.410.920.820.530.610.190.540.20.51-0.990.49-0.120.43-0.45
0.920.88-0.23-0.870.830.79-0.220.840.620.380.70.910.960.560.870.510.84-0.530.8-0.230.43-0.97
-0.92-0.880.270.88-0.82-0.820.22-0.84-0.66-0.34-0.73-0.83-0.97-0.66-0.88-0.57-0.860.55-0.750.3-0.45-0.97
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Competition

Immunoprecise Common Stock Shares Outstanding

Common Stock Shares Outstanding

26.92 Million

At present, Immunoprecise Antibodies' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting.
According to the company disclosure, Immunoprecise Antibodies has an Earnings Per Share of -0.77 times. This is 109.2% lower than that of the Biotechnology sector and 83.92% lower than that of the Health Care industry. The earnings per share for all United States stocks is 124.68% higher than that of the company.

Immunoprecise Earnings Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunoprecise Antibodies' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunoprecise Antibodies could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics of similar companies.
Immunoprecise Antibodies is currently under evaluation in earnings per share category among its peers.

Immunoprecise Antibodies Current Valuation Drivers

We derive many important indicators used in calculating different scores of Immunoprecise Antibodies from analyzing Immunoprecise Antibodies' financial statements. These drivers represent accounts that assess Immunoprecise Antibodies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunoprecise Antibodies' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap49.9M52.8M197.4M140.7M86.7M45.2M
Enterprise Value47.3M54.7M159.1M113.3M85.6M55.4M

Immunoprecise Fundamentals

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:
Check out Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis.
For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
0.921
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.13)
Return On Equity
(0.64)
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.